These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pertuzumab: development beyond breast cancer. Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675 [TBL] [Abstract][Full Text] [Related]
3. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer. De Mattos-Arruda L; Cortes J Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722 [TBL] [Abstract][Full Text] [Related]
4. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer. Chung C; Lam MS Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598 [TBL] [Abstract][Full Text] [Related]
5. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers]. Sabatier R; Gonçalves A Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659 [TBL] [Abstract][Full Text] [Related]
6. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Herbst RS; Davies AM; Natale RB; Dang TP; Schiller JH; Garland LL; Miller VA; Mendelson D; Van den Abbeele AD; Melenevsky Y; de Vries DJ; Eberhard DA; Lyons B; Lutzker SG; Johnson BE Clin Cancer Res; 2007 Oct; 13(20):6175-81. PubMed ID: 17947484 [TBL] [Abstract][Full Text] [Related]
8. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333 [TBL] [Abstract][Full Text] [Related]
9. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer. Dawood S; Sirohi B Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974 [TBL] [Abstract][Full Text] [Related]
11. Pertuzumab and trastuzumab: the rationale way to synergy. Richard S; Selle F; Lotz JP; Khalil A; Gligorov J; Soares DG An Acad Bras Cienc; 2016; 88 Suppl 1():565-77. PubMed ID: 27275646 [TBL] [Abstract][Full Text] [Related]
12. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer. O'Sullivan CC; Connolly RM Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725 [TBL] [Abstract][Full Text] [Related]
13. Pertuzumab in HER2-positive breast cancer. Sendur MA; Aksoy S; Altundag K Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713 [TBL] [Abstract][Full Text] [Related]
15. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Baselga J; Swain SM Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694 [TBL] [Abstract][Full Text] [Related]
16. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Gerratana L; Bonotto M; Bozza C; Ongaro E; Fanotto V; Pelizzari G; Puglisi F Expert Opin Biol Ther; 2017 Mar; 17(3):365-374. PubMed ID: 28092723 [TBL] [Abstract][Full Text] [Related]
17. Pertuzumab for the treatment of breast cancer: a safety review. Gao J; Swain SM Expert Opin Drug Saf; 2016 Jun; 15(6):853-63. PubMed ID: 26982349 [TBL] [Abstract][Full Text] [Related]
18. Pertuzumab for the treatment of metastatic breast cancer. Langdon SP; Cameron DA Expert Rev Anticancer Ther; 2013 Aug; 13(8):907-18. PubMed ID: 23984893 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890 [TBL] [Abstract][Full Text] [Related]